Flux across of microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro

被引:38
作者
Banks, Stan L. [1 ]
Pinninti, Raghotham R. [1 ]
Gill, Harvinder S. [2 ,3 ]
Crooks, Peter A. [1 ]
Prausnitz, Mark R. [2 ,4 ]
Stinchcomb, Audra L. [1 ]
机构
[1] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA
[2] Georgia Tech Res Inst, Wallace Coulter Sch Biomed Engn, Atlanta, GA 30332 USA
[3] Emory Univ, Georgia Inst Technol, Atlanta, GA 30332 USA
[4] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA
关键词
microneedle; 6-beta-naltrexol; naltrexone; protonation; transdermal;
D O I
10.1007/s11095-008-9578-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this investigation was to evaluate the in vitro microneedle (MN) enhanced percutaneous absorption of naltrexone hydrochloride salt (NTX center dot HCl) compared to naltrexone base (NTX) in hairless guinea pig skin (GP) and human abdominal skin. In a second set of experiments, permeability of the major active metabolite 6-beta-naltrexol base (NTXOL) in the primarily unionized (unprotonated) form at pH 8.5 was compared to the ionized form (pH 4.5). Methods. In vitro fluxes of NTX, NTX center dot HCl and ionized and unionized NTXOL were measured through microneedle treated or intact full thickness human and GP skin using a flow through diffusion apparatus. Solubility and diffusion samples were analyzed by HPLC. Results. Both GP and human skin show significant increases in flux when treated with 100 MN insertions as compared to intact full thickness skin when treated with NTX center dot HCl or ionized NTXOL (pH 4.5; p < 0.05). MN increased GP skin permeability for the hydrophilic HCL salt of NTX by tenfold and decreased lag time by tenfold too. Similar results were found using human skin, such that skin permeability to NTX center dot HCl was elevated to 7.0x10(-5) cm/h. Permeability of the primarily unionized (unprotonated) form of NTXOL at pH 8.5 was increased by MN only threefold and lag time was only modestly reduced. However, MN treatment with the primarily ionized (protonated) form of NTXOL at pH 4.5 increased skin permeability fivefold and decreased lag time fourfold. Conclusion. Enhancement was observed in vitro in both GP and human skin treated with MN compared to intact skin with the salt form of NTX and the ionized form of NTXOL. We conclude that transdermal flux can be optimized by using MN in combination with charged (protonated) drugs that have increased solubility in an aqueous patch reservoir and increased permeability through aqueous pathways created by MN in the skin.
引用
收藏
页码:1677 / 1685
页数:9
相关论文
共 26 条
[1]  
*ACS, 2007, CANC FACTS FIG 2007, P1
[2]  
ALKERMES C, VIVITROL
[3]   Structure of the skin barrier and its modulation by vesicular formulations [J].
Bouwstra, JA ;
Honeywell-Nguyen, PL ;
Gooris, GS ;
Ponec, M .
PROGRESS IN LIPID RESEARCH, 2003, 42 (01) :1-36
[4]   METHODS FOR INVITRO PERCUTANEOUS-ABSORPTION STUDIES .3. HYDROPHOBIC COMPOUNDS [J].
BRONAUGH, RL ;
STEWART, RF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (09) :1255-1258
[5]   Transdermal delivery of desmopressin using a coated microneedle array patch system [J].
Cormier, M ;
Johnson, B ;
Ameri, M ;
Nyam, K ;
Libiran, L ;
Zhang, DD ;
Daddona, P .
JOURNAL OF CONTROLLED RELEASE, 2004, 97 (03) :503-511
[6]  
Coulman Sion A., 2006, Current Drug Delivery, V3, P65, DOI 10.2174/156720106775197510
[7]   PROBES FOR NARCOTIC RECEPTOR MEDIATED PHENOMENA .18. EPIMERIC 6-ALPHA-IODO-3,14-DIHYDROXY-17-(CYCLOPROPYLMETHYL)-4,5-ALPHA-EPOXYMORPHINANS AND 6-BETA-IODO-3,14-DIHYDROXY-17-(CYCLOPROPYLMETHYL)-4,5-ALPHA-EPOXYMORPHINANS AS POTENTIAL LIGANDS FOR OPIOID RECEPTOR SINGLE PHOTON-EMISSION COMPUTED-TOMOGRAPHY - SYNTHESIS, EVALUATION, AND RADIOCHEMISTRY OF [I-125] 6-BETA-IODO-3,14-DIHYDROXY-17-(CYCLOPROPYLMETHYL)-4,5-ALPHA-EPOXYMORPHINAN [J].
DECOSTA, BR ;
IADAROLA, MJ ;
ROTHMAN, RB ;
BERMAN, KF ;
GEORGE, C ;
NEWMAN, AH ;
MAHBOUBI, A ;
JACOBSON, AE ;
RICE, KC .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (15) :2826-2835
[8]   Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial [J].
Galloway, Gantt P. ;
Koch, Monika ;
Cello, Ryan ;
Smith, David E. .
BMC PSYCHIATRY, 2005, 5 (1)
[9]   Silicon micromachined hollow microneedles for transdermal liquid transport [J].
Gardeniers, HJGE ;
Luttge, R ;
Berenschot, EJW ;
de Boer, MJ ;
Yeshurun, SY ;
Hefetz, M ;
van't Oever, R ;
van den Berg, A .
JOURNAL OF MICROELECTROMECHANICAL SYSTEMS, 2003, 12 (06) :855-862
[10]   Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent [J].
Hammell, DC ;
Stolarczyk, EI ;
Klausner, M ;
Hamad, MO ;
Crooks, PA ;
Stinchcomb, AL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (04) :828-836